South Asian Journal of Cancer

TRENDS IN HORMONAL THERAPY IN PROSTATE CANCER: REVIEW ARTICLE
Year
: 2015  |  Volume : 4  |  Issue : 2  |  Page : 95--97

Emerging potential of parenteral estrogen as androgen deprivation therapy for prostate cancer


Syed Imran Ali Shah 
 Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London W12 ONN, United Kingdom

Correspondence Address:
Syed Imran Ali Shah
Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London W12 ONN
United Kingdom

Androgen deprivation therapy (ADT) is a key management strategy for prostate cancer (PC), achieved commonly by administration of luteinizing hormone-releasing hormone agonist (LHRHa), ADT markedly suppresses both male and female sex hormones which results in «DQ»castration syndrome«DQ», a constellation of adverse events such as muscle weakness, impairment of glucose and lipid metabolism, impotence, osteoporosis, and fractures. Recent evidence suggests that estrogen, in the parenteral form, may emerge as an alternative to LHRHa as it offers potential benefits of arresting PC growth as well as avoiding some of the estrogen deficiency related toxicities of LHRHa by maintaining endogenous levels of estrogen.


How to cite this article:
Ali Shah SI. Emerging potential of parenteral estrogen as androgen deprivation therapy for prostate cancer.South Asian J Cancer 2015;4:95-97


How to cite this URL:
Ali Shah SI. Emerging potential of parenteral estrogen as androgen deprivation therapy for prostate cancer. South Asian J Cancer [serial online] 2015 [cited 2019 Sep 15 ];4:95-97
Available from: http://journal.sajc.org/article.asp?issn=2278-330X;year=2015;volume=4;issue=2;spage=95;epage=97;aulast=Ali;type=0